USD 4.34
↓ -0.2 (-4.41%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| ACB | -4.4 | -14.6 | -20.9 | -37.7 | -39.0 | -6.7 | -94.6 | -98.7 | -96.0 | -98.5 |
| S&P 500 | -0.6 | -0.5 | 2.3 | 7.3 | 12.1 | 32.1 | 27.0 | 90.7 | 191.4 | 33587.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | ACB |
| name | Aurora Cannabis Inc. |
| price | 4.34 |
| changes percentage | -4.41 |
| change | -0.20 |
| day low | 4.34 |
| day high | 4.53 |
| year high | 9.35 |
| year low | 2.84 |
| market cap | 237227872 |
| price avg 50 | 5.57 |
| price avg 200 | 5.51 |
| exchange | NASDAQ |
| volume | 987198 |
| avg volume | 1024337 |
| open | 4.50 |
| previous close | 4.54 |
| eps | -0.48 |
| pe | -9.04 |
| earnings announcement | 2025-02-06T12:00:00.000+0000 |
| shares outstanding | 54660800 |
| timestamp | 2024-11-14 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001683541 | |||
| revenue | 270281000 | 233290083 | 15.86 |
| gross profit | 131460000 | -64359839 | 304.26 |
| gross profit ratio | 0.49 | -0.28 | 276.30 |
| research and development expenses | 3572000 | 6561316 | -45.56 |
| operating expenses | 158539000 | 189958191 | -16.54 |
| interest income | 12813000 | 19002619 | -32.57 |
| interest expense | 14186000 | 39461234 | -64.05 |
| ebitda | 20474000 | -210744810 | 109.72 |
| ebitdaratio | 0.08 | -0.9 | 108.39 |
| operating income | -46453000 | -254318030 | 81.73 |
| operating income ratio | -0.17 | -1.09 | 84.23 |
| net income | -69326000 | -265328670 | 73.87 |
| net income ratio | -0.26 | -1.14 | 77.45 |
| eps | -1.46 | -8.22 | 82.24 |
Revenue Growth: revenue increased to 270 million in 2023 from 233 million in 2022 representing a change of 15.86%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 131 million in 2023 from -64 million in 2022 representing a change of 304.26%. This indicates a sales profitability growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 159 million in 2023 from 190 million in 2022 representing a change of -16.54%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 20 million in 2023 from -211 million in 2022 representing a change of 109.72%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -46 million in 2023 from -254 million in 2022 representing a change of 81.73%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -69 million in 2023 from -265 million in 2022 representing a change of 73.87%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -1.46 in 2023 from -1.46 in 2022 representing a change of 82.24%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 4 million in 2023 from 7 million in 2022 representing a change of -45.56%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
| 2023Q3 | 2023Q2 | Q/Q change % | |
|---|---|---|---|
| 0001683541 | |||
| revenue | 67411000 | 64419000 | 4.64 |
| gross profit | 51167000 | 19803000 | 158.38 |
| gross profit ratio | 0.76 | 0.31 | 146.91 |
| research and development expenses | 743000 | 782000 | -4.99 |
| operating expenses | 43746000 | 42126000 | 3.85 |
| interest income | 2889000 | 3326000 | -13.14 |
| interest expense | 2057000 | 2573000 | -20.05 |
| ebitda | 16311000 | -7864000 | 307.41 |
| ebitdaratio | 0.24 | -0.12 | 298.21 |
| operating income | 3150000 | -23890000 | 113.19 |
| operating income ratio | 0.05 | -0.37 | 112.60 |
| net income | -17406000 | -24499000 | 28.95 |
| net income ratio | -0.26 | -0.38 | 32.11 |
| eps | -0.37 | -0.52 | 28.85 |
Revenue Growth: revenue increased to 67 million in 2023Q3 from 64 million in 2023Q2 representing a change of 4.64%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 51 million in 2023Q3 from 20 million in 2023Q2 representing a change of 158.38%. This indicates a sales profitability growth, which is a positive sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 16 million in 2023Q3 from -8 million in 2023Q2 representing a change of 307.41%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to 3 million in 2023Q3 from -24 million in 2023Q2 representing a change of 113.19%. The increase in operating income indicates better operational performance and increased profitability.
Earnings per Share (EPS): EPS increased to -0.37 in 2023Q3 from -0.37 in 2023Q2 representing a change of 28.85%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 1 million in 2023Q3 from 1 million in 2023Q2 representing a change of -4.99%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 44 million in 2023Q3 from 42 million in 2023Q2 representing a change of 3.85%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Net Income: Net income decreased to -17 million in 2023Q3 from -24 million in 2023Q2 representing a change of 28.95%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001683541 | |||
| total assets | 838673000 | 926322000 | -9.46 |
| total liabilities | 236803000 | 409185000 | -42.13 |
| total equity | 601870000 | 517137000 | 16.39 |
| cash and cash equivalents | 113439000 | 300842000 | -62.29 |
| short term investments | 4036000 | 0 | NaN |
| long term investments | 6343000 | 13745000 | -53.85 |
| total current assets | 426605000 | 479927000 | -11.11 |
| total non current assets | 412068000 | 446395000 | -7.69 |
| total current liabilities | 124620000 | 242305000 | -48.57 |
| total non current liabilities | 112183000 | 166880000 | -32.78 |
| common stock | 6971416000 | 6841234000 | 1.90 |
| retained earnings | -6367936000 | -6296833000 | -1.13 |
| total debt | 104791000 | 227522000 | -53.94 |
Total Assets: Total Assets decreased to 839 million in 2023 from 926 million in 2022 representing a change of -9.46%. Suggesting a decrease in asset holdings.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 113 million in 2023 from 301 million in 2022 representing a change of -62.29%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 427 million in 2023 from 480 million in 2022 representing a change of -11.11%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -6,368 million in 2023 from -6,297 million in 2022 representing a change of -1.13%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 237 million in 2023 from 409 million in 2022 representing a change of -42.13%. This indicates a decrease in overall liabilities.
Total Equity: Total Equity increased to 602 million in 2023 from 517 million in 2022 representing a change of 16.39%. This indicates an increase in shareholders' equity.
Short Term Investments: Short Term Investments increased to 4 million in 2023 from 0 million in 2022 representing a change of nan%. This indicates an increase in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities decreased to 125 million in 2023 from 242 million in 2022 representing a change of -48.57%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 6,971 in 2023 from 6,841 in 2022 representing a change of 1.9%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 105 million in 2023 from 228 million in 2022 representing a change of -53.94%. This indicates a reduction in overall debt burden.
| 2023Q3 | 2023Q2 | Q/Q change % | |
|---|---|---|---|
| 0001683541 | |||
| total assets | 838673000 | 817167000 | 2.63 |
| total liabilities | 236803000 | 258977000 | -8.56 |
| total equity | 601870000 | 558190000 | 7.83 |
| cash and cash equivalents | 113439000 | 144368000 | -21.42 |
| short term investments | 4036000 | 4183000 | -3.51 |
| long term investments | 6343000 | 7827000 | -18.96 |
| total current assets | 426605000 | 406530000 | 4.94 |
| total non current assets | 412068000 | 410637000 | 0.35 |
| total current liabilities | 124620000 | 107377000 | 16.06 |
| total non current liabilities | 112183000 | 151600000 | -26.00 |
| common stock | 6971416000 | 6938763000 | 0.47 |
| retained earnings | -6367936000 | -6367806000 | -0.00 |
| total debt | 104791000 | 103340000 | 1.40 |
Total Assets: Total Assets increased to 839 million in 2023Q3 from 817 million in 2023Q2 representing a change of 2.63%. Suggesting a growth in asset holdings.
Total Liabilities: Total Liabilities decreased to 237 million in 2023Q3 from 259 million in 2023Q2 representing a change of -8.56%. This indicates a decrease in overall liabilities.
Total Equity: Total Equity increased to 602 million in 2023Q3 from 558 million in 2023Q2 representing a change of 7.83%. This indicates an increase in shareholders' equity.
Total Current Assets: Total Current Assets increased to 427 million in 2023Q3 from 407 million in 2023Q2 representing a change of 4.94%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 6,971 in 2023Q3 from 6,939 in 2023Q2 representing a change of 0.47%. This indicates an increase in ownership interest.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 113 million in 2023Q3 from 144 million in 2023Q2 representing a change of -21.42%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 4 million in 2023Q3 from 4 million in 2023Q2 representing a change of -3.51%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 125 million in 2023Q3 from 107 million in 2023Q2 representing a change of 16.06%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -6,368 million in 2023Q3 from -6,368 million in 2023Q2 representing a change of -0.0%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 105 million in 2023Q3 from 103 million in 2023Q2 representing a change of 1.4%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001683541 | |||
| net change in cash | -121503000 | -140009000 | 13.22 |
| operating cash flow | -68508000 | -115821000 | 40.85 |
| free cash flow | -85464000 | -127953000 | 33.21 |
| capital expenditure | -16956000 | -12132000 | -39.76 |
| depreciation and amortization | 33071000 | 43573224 | -24.10 |
| deferred income tax | -1667000 | -18404000 | 90.94 |
| stock based compensation | 12717000 | 16889329 | -24.70 |
| accounts payables | -15699000 | -8064000 | -94.68 |
| inventory | 3615000 | 49028000 | -92.63 |
| acquisitions net | -5545000 | -18537000 | 70.09 |
| investments in property plant and equipment | -16956000 | -12132000 | -39.76 |
| net cash used for investing activites | -5487000 | -27291000 | 79.89 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 37926000 | 73187000 | -48.18 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -47923000 | -56478000 | 15.15 |
| cash at end of period | 113439000 | 300842000 | -62.29 |
| accounts receivables | -4333000 | 5528000 | -178.38 |
| cash at beginning of period | 234942000 | 440851000 | -46.71 |
Net Change in Cash: Net Change in Cash increased to -122 million in 2023 from -140 million in 2022 representing a change of 13.22%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -69 million in 2023 from -116 million in 2022 representing a change of 40.85%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -85 million in 2023 from -128 million in 2022 representing a change of 33.21%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -17 million in 2023 from -12 million in 2022 representing a change of -39.76%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 13 million in 2023 from 17 million in 2022 representing a change of -24.7%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Receivables: Accounts Receivables decreased to -4 million in 2023 from 6 million in 2022 representing a change of -178.38%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Deferred Income Tax: Deferred Income Tax increased to -2 million in 2023 from -18 million in 2022 representing a change of 90.94%. This indicates that the company's tax liability for future periods has increased.
Accounts Payables: The absolute value of Accounts Payables increased to 16 million in 2023 from 8 million in 2022 representing a change of -94.68%. This indicates that the company has increased its outstanding obligations to its suppliers.
| 2023Q3 | 2023Q2 | Q/Q change % | |
|---|---|---|---|
| 0001683541 | |||
| operating cash flow | -21126000 | -5264000 | -301.33 |
| free cash flow | -26812000 | -8051000 | -233.03 |
| capital expenditure | -5686000 | -2787000 | -104.02 |
| depreciation and amortization | 6894000 | 8640000 | -20.21 |
| deferred income tax | -1549000 | -44000 | -3,420.45 |
| stock based compensation | 3029000 | 2839000 | 6.69 |
| accounts receivables | -1698000 | -3589000 | 52.69 |
| accounts payables | -3229000 | 14548000 | -122.20 |
| inventory | -5013000 | -4499000 | -11.42 |
| acquisitions net | -5545000 | 8859000 | -162.59 |
| investments in property plant and equipment | -5686000 | -2787000 | -104.02 |
| net cash used for investing activites | -6237000 | 6887000 | -190.56 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -466000 | 36844000 | -101.26 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -4872000 | 15157000 | -132.14 |
| net change in cash | -30929000 | 15450000 | -300.19 |
| cash at end of period | 113439000 | 144368000 | -21.42 |
| cash at beginning of period | 144368000 | 128918000 | 11.98 |
Net Change in Cash: Net Change in Cash decreased to -31 million in 2023Q3 from 15 million in 2023Q2 representing a change of -300.19%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -21 million in 2023Q3 from -5 million in 2023Q2 representing a change of -301.33%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -27 million in 2023Q3 from -8 million in 2023Q2 representing a change of -233.03%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 3 million in 2023Q3 from 3 million in 2023Q2 representing a change of 6.69%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Receivables: Accounts Receivables increased to -2 in 2023Q3 from -4 million in 2023Q2 representing a change of 52.69%. This suggests that the company is less capable of collecting payments from its customers.
Capital Expenditure: Capital Expenditure decreased to -6 million in 2023Q3 from -3 million in 2023Q2 representing a change of -104.02%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Payables: The absolute value of Accounts Payables decreased to 3 million in 2023Q3 from 15 million in 2023Q2 representing a change of -122.2%. This indicates that the company has reduced its outstanding obligations to its suppliers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q2 2025 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2024-03-31 | 2023-03-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 5.7 | 7.23 | -21.15 |
| net income per share | -1.46 | -8.22 | 82.22 |
| operating cash flow per share | -1.44 | -3.59 | 59.75 |
| free cash flow per share | -1.8 | -3.96 | 54.54 |
| cash per share | 2.48 | 9.32 | -73.43 |
| book value per share | 12.69 | 16.02 | -20.79 |
| tangible book value per share | 10.92 | 13.54 | -19.36 |
| shareholders equity per share | 11.8 | 15.06 | -21.63 |
| interest debt per share | 2.51 | 6.92 | -63.72 |
| market cap | 277361140.92 | 304024066.27 | -8.77 |
| enterprise value | 268713140.92 | 230704066.27 | 16.48 |
| pe ratio | -4.0 | -1.15 | -249.16 |
| price to sales ratio | 1.03 | 1.3 | -21.26 |
| pocfratio | -4.05 | -2.62 | -54.24 |
| pfcf ratio | -3.25 | -2.38 | -36.59 |
| pb ratio | 0.5 | 0.63 | -20.78 |
| ptb ratio | 0.5 | 0.63 | -20.78 |
| ev to sales | 0.99 | 0.99 | 0.53 |
| enterprise value over ebitda | 13.12 | -1.09 | 1,298.91 |
| ev to operating cash flow | -3.92 | -1.99 | -96.92 |
| ev to free cash flow | -3.14 | -1.8 | -74.38 |
| earnings yield | -0.25 | -0.87 | 71.36 |
| free cash flow yield | -0.31 | -0.42 | 26.79 |
| debt to equity | 0.19 | 0.38 | -50.47 |
| debt to assets | 0.12 | 0.2 | -37.00 |
| net debt to ebitda | -0.42 | 0.35 | -221.41 |
| current ratio | 3.42 | 1.98 | 72.83 |
| interest coverage | -3.27 | -6.44 | 49.19 |
| income quality | 1.16 | 0.44 | 165.80 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.39 | 0.29 | 32.77 |
| research and ddevelopement to revenue | 0.01 | 0.03 | -53.01 |
| intangibles to total assets | 0.1 | 0.09 | 15.84 |
| capex to operating cash flow | -0.25 | -0.1 | -136.29 |
| capex to revenue | 0.06 | 0.05 | 20.63 |
| capex to depreciation | 0.51 | 0.28 | 84.15 |
| stock based compensation to revenue | 0.05 | 0.07 | -35.01 |
| graham number | 19.7 | 52.78 | -62.67 |
| roic | -0.07 | -0.35 | 80.41 |
| return on tangible assets | -0.09 | -0.31 | 70.70 |
| graham net net | 0.17 | -0.4 | 141.70 |
| working capital | 301985000 | 237622000 | 27.09 |
| tangible asset value | 517840000 | 437019000 | 18.49 |
| net current asset value | 189802000 | 70742000 | 168.30 |
| invested capital | 680339000 | 640709000 | 6.19 |
| average receivables | 43378000 | 44198500 | -1.86 |
| average payables | 21133500 | 17900000 | 18.06 |
| average inventory | 157599000 | 134373500 | 17.28 |
| days sales outstanding | 61.33 | 64.69 | -5.20 |
| days payables outstanding | 53.44 | 26.91 | 98.61 |
| days of inventory on hand | 490.04 | 157.97 | 210.21 |
| receivables turnover | 5.95 | 5.64 | 5.48 |
| payables turnover | 6.83 | 13.57 | -49.65 |
| inventory turnover | 0.74 | 2.31 | -67.76 |
| roe | -0.12 | -0.55 | 77.31 |
| capex per share | 0.36 | 0.38 | -4.88 |
ROE: Return on Equity (ROE) increased to -0.12 on 2024-03-31 from -0.55 on 2023-03-31, representing a change of 77.31%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -4.00 on 2024-03-31 from -1.15 on 2023-03-31, representing a change of -249.16%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 3.42 on 2024-03-31 from 1.98 on 2023-03-31, representing a change of 72.83%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.19 on 2024-03-31 from 0.38 on 2023-03-31, representing a change of -50.47%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-03-31 Q3 | 2023-12-31 Q2 | Q/Q change % | |
|---|---|---|---|
| ACB | |||
| calendar year | 2023 | 2023 | NaN |
| revenue per share | 1.42 | 1.36 | 4.64 |
| net income per share | -0.37 | -0.52 | 28.95 |
| operating cash flow per share | -0.45 | -0.11 | -301.33 |
| free cash flow per share | -0.57 | -0.17 | -233.03 |
| cash per share | 2.48 | 3.13 | -20.92 |
| book value per share | 12.69 | 11.77 | 7.83 |
| tangible book value per share | 10.92 | 10.1 | 8.10 |
| shareholders equity per share | 11.8 | 10.89 | 8.39 |
| interest debt per share | 2.25 | 2.23 | 0.88 |
| market cap | 277361140.92 | 298850503.98 | -7.19 |
| enterprise value | 268713140.92 | 257822503.98 | 4.22 |
| pe ratio | -3.98 | -3.05 | -30.63 |
| price to sales ratio | 4.11 | 4.64 | -11.31 |
| pocfratio | -13.13 | -56.77 | 76.87 |
| pfcf ratio | -10.34 | -37.12 | 72.13 |
| pb ratio | 0.5 | 0.58 | -14.37 |
| ptb ratio | 0.5 | 0.58 | -14.37 |
| ev to sales | 3.99 | 4.0 | -0.40 |
| enterprise value over ebitda | 16.47 | -32.79 | 150.25 |
| ev to operating cash flow | -12.72 | -48.98 | 74.03 |
| ev to free cash flow | -10.02 | -32.02 | 68.70 |
| earnings yield | -0.06 | -0.08 | 23.45 |
| free cash flow yield | -0.1 | -0.03 | -258.83 |
| debt to equity | 0.19 | 0.2 | -6.44 |
| debt to assets | 0.12 | 0.13 | -1.20 |
| net debt to ebitda | -0.53 | 5.22 | -110.16 |
| current ratio | 3.42 | 3.79 | -9.58 |
| interest coverage | 1.53 | -9.28 | 116.49 |
| income quality | 1.58 | 0.21 | 659.24 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.43 | 0.39 | 9.23 |
| research and ddevelopement to revenue | 0.01 | 0.01 | -9.20 |
| intangibles to total assets | 0.1 | 0.1 | 3.46 |
| capex to operating cash flow | -0.27 | -0.53 | 49.16 |
| capex to revenue | 0.08 | 0.04 | 94.96 |
| capex to depreciation | 0.82 | 0.32 | 155.69 |
| stock based compensation to revenue | 0.04 | 0.04 | 1.96 |
| graham number | 9.87 | 11.25 | -12.25 |
| roic | 0.0 | -0.04 | 111.71 |
| return on tangible assets | -0.02 | -0.03 | 30.52 |
| graham net net | 0.17 | -0.13 | 232.87 |
| working capital | 301985000 | 299153000 | 0.95 |
| tangible asset value | 517840000 | 479051000 | 8.10 |
| net current asset value | 189802000 | 147553000 | 28.63 |
| invested capital | 680339000 | 673933000 | 0.95 |
| average receivables | 44364500 | 41519000 | 6.85 |
| average payables | 21516500 | 18693000 | 15.10 |
| average inventory | 165166000 | 141591500 | 16.65 |
| days sales outstanding | 60.63 | 60.52 | 0.18 |
| days payables outstanding | 112.61 | 45.81 | 145.84 |
| days of inventory on hand | 1032.62 | 290.39 | 255.60 |
| receivables turnover | 1.48 | 1.49 | -0.18 |
| payables turnover | 0.8 | 1.96 | -59.32 |
| inventory turnover | 0.09 | 0.31 | -71.88 |
| roe | -0.03 | -0.05 | 34.45 |
| capex per share | 0.12 | 0.06 | 104.02 |
ROE: Return on Equity (ROE) increased to -0.03 on 2024-03-31 Q3 from -0.05 on 2023-12-31 Q2, representing a change of 34.45%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -3.98 on 2024-03-31 Q3 from -3.05 on 2023-12-31 Q2, representing a change of -30.63%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 3.42 on 2024-03-31 Q3 from 3.79 on 2023-12-31 Q2, representing a change of -9.58%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.19 on 2024-03-31 Q3 from 0.20 on 2023-12-31 Q2, representing a change of -6.44%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-11 12:41:22
Aurora Cannabis dropped over 10%, along with the broader cannabis market, due to concerns over U.S. election results. Despite this, Aurora has no U.S. cannabis operations and is unaffected. Aurora reported robust revenue growth, with a 29% YoY increase, driven by a 93% rise in international medical cannabis sales. The company re-affirmed positive free cash flow expectations for Q3 and demonstrated strong spending discipline, maintaining positive adjusted EBITDA for the 8th consecutive quarter.
Sentiment: Positive
Publish Date: 2024-11-07 12:14:17
Amendment 3 – which would have legalized the recreational use of marijuana in the state's constitution – failed to receive the 60% support needed to pass under Florida law.
Sentiment: Negative
Publish Date: 2024-11-06 09:46:13
Aurora Cannabis Inc. (ACB) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to loss of $0.50 per share a year ago.
Sentiment: Negative
Publish Date: 2024-11-06 09:42:30
Shares in cannabis stocks such as Trulieve Cannabis Corp. (CSE:TRUL), Curaleaf Hldgs Inc. (CSE:CURA, OTCQX:CURLF) and Verano Holdings Corp (CSE:VRNO, OTCQX:VRNOF) tanked after Florida rejected legalization of recreational marijuana. A ballot measure, known as Amendment 3, which would have allowed adults to possess up to three ounces of marijuana, failed to obtain the required 60% of support from voters yesterday.
Sentiment: Positive
Publish Date: 2024-11-06 09:37:31
Aurora Cannabis Inc. (NASDAQ:ACB ) Q2 2025 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Kevin Niland - Director, Strategic Finance and IR Miguel Martin - CEO Simona King - CFO Conference Call Participants Frederico Gomes - ATB Capital Markets Pablo Zuanic - Zuanic & Associates Operator Greetings and welcome to the Aurora Cannabis Inc. Second Quarter 2025 Results Conference Call. all participants will be in a listen-only mode and a question-and-answer session will follow the formal presentation.
Sentiment: Positive
Publish Date: 2024-11-06 07:00:00
NASDAQ | TSX: ACB Record Adjusted EBITDA1 of $10.1 Million, a YoY increase of 210% Quarterly Net Revenue1 up 29% YoY to $81.1 Million, with 41% growth in Global Medical Cannabis Re-Affirms Target of Positive Free Cash Flow1 in the Quarter Ending December 31, 2024 Maintains Strong Balance Sheet with ~$152 Million of Cash and a Debt-Free Cannabis Business2 EDMONTON, AB , Nov. 6, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter fiscal 2025. "Our strong quarterly results demonstrate Aurora's leadership in global medical cannabis and ability to capitalize on opportunities within rapidly growing markets such as Australia, Germany, Poland, and the UK.
Sentiment: Neutral
Publish Date: 2024-10-24 17:45:00
NASDAQ | TSX: ACB EDMONTON, AB , Oct. 24, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today announced today that it has scheduled a conference call to discuss the results for its second quarter 2025 on Wednesday, November 6, 2024 at 8:00 a.m. Eastern Time | 6:00 a.m.
Sentiment: Positive
Publish Date: 2024-10-17 13:01:30
ACB and MedReleaf Australia launch premium medical cannabis oils, offering tailored cannabinoid formulations for patient care.
Sentiment: Positive
Publish Date: 2024-10-16 07:00:00
NASDAQ | TSX: ACB Canada's Leading Medical Cannabis Company and MedReleaf Australia Launch New Oil Products for Enhanced Patient Care Options EDMONTON, AB , Oct. 16, 2024 /CNW/ - Aurora Cannabis Inc., (NASDAQ: ACB) (TSX: ACB) – the Canadian based global leader in medical cannabis, in conjunction with MedReleaf Australia, is pleased to announce an enhanced product range of premium medical cannabis oil in Australia. This expansion reinforces Aurora's dedication to providing high-quality, innovative cannabis solutions to patients around the world.
Sentiment: Neutral
Publish Date: 2024-10-09 07:45:00
This Canadian pot stock has defied the broader downturn among its peer group in 2024.
Sentiment: Positive
Publish Date: 2024-10-03 11:29:41
The cannabis sector has captivated investors, promising a green rush of potential profits. However, the path to profitability has been rocky, marked by regulatory hurdles, intense competition, and, at times, a volatile market.
Sentiment: Positive
Publish Date: 2024-10-03 10:50:59
Aurora Cannabis' new collaboration on the Genome BC-Funded Project addresses distinct cannabis aromas.
Sentiment: Positive
Publish Date: 2024-10-02 10:09:36
The cannabis sector has captivated investors, promising a green rush of potential profits. However, the path to profitability has been rocky, marked by regulatory hurdles, intense competition, and, at times, a volatile market.
Sentiment: Positive
Publish Date: 2024-10-02 07:00:00
NASDAQ | TSX: ACB Research Project designed to validate breeding genetics connected with fruity aroma, a key patient and consumer preference trait, with positive impact on future innovation EDMONTON, AB , Oct. 2, 2024 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) –—the Canadian based leading global medical cannabis company, today announced a research grant provided to the University of British Columbia (UBC) by Genome British Columbia (Genome BC), a not-for-profit organization supporting world-class genomics research and innovation in British Columbia. The project, Genomics-enabled Aroma Breeding in Cannabis, will directly support Aurora's genetics work the project, is led by Drs.
Sentiment: Positive
Publish Date: 2024-09-20 07:00:00
NASDAQ | TSX: ACB Outgoing Chairman Ron Funk appointed Lead Independent Director, as part of Board leadership transition EDMONTON, AB , Sept. 20, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced the appointments of CEO Miguel Martin to the additional role of Executive Chairman and outgoing Chairman Ron Funk as Lead Independent Director.
Sentiment: Positive
Publish Date: 2024-09-19 10:00:45
The Canadian cannabis market remains a focal point for investors this week, especially with companies expanding into the U.S. market. Recently, the U.S. cannabis industry has shown remarkable growth, with sales projected to reach $45 billion by 2025. This expansion offers Canadian companies a gateway to a larger consumer base. The increasing push for legalization in the U.S. is also a significant factor. States are continuously passing legislation to legalize cannabis for recreational and medicinal use. Therefore, investors watch how Canadian stocks position themselves for potential U.S. market entry.
Sentiment: Positive
Publish Date: 2024-09-17 07:00:00
Auto-Flowering Breakthroughs Poised to Transform Cannabis Cultivation in High-Latitude Regions, Opening New Doors for Advanced Breeding Strategies EDMONTON, AB , Sept. 17, 2024 /PRNewswire/ -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) –the Canadian based leading global medical cannabis company, is pioneering ground-breaking research in auto-flowering technology.
Sentiment: Positive
Publish Date: 2024-09-10 09:15:45
24/7 Wall St. Insights A Kamala Harris victory in the 2024 presidential election could provide a boost for stocks in a variety of sectors.
Sentiment: Positive
Publish Date: 2024-09-09 07:03:00
Launch represents Vectura Fertin Pharma's first medical cannabis CBD lozenge to be introduced in Canada Launch follows announcement of commercial collaboration between Cogent International, a Vectura Fertin Pharma subsidiary, and Aurora to leverage Aurora's Canadian medical cannabis patient platform Collaboration will explore the potential to launch Vectura Fertin Pharma's future medical cannabis portfolio in Canada Edmonton, AB, and Stamford, CT – September 9, 2024 - Aurora Cannabis Inc. ("Aurora") (NASDAQ | TSX: ACB), a leading Canadian-based global medical cannabis company, and Vectura Fertin Pharma, Inc., an innovator in wellness and healthcare, are pleased to announce the launch of the newly developed Luo CBD lozenge. The high-quality CBD lozenge was developed by Vectura Fertin Pharma and adheres to stringent safety, quality and regulatory standards to address unmet medical and health needs.
Sentiment: Positive
Publish Date: 2024-09-09 07:00:00
Launch represents Vectura Fertin Pharma's first medical cannabis CBD lozenge to be introduced in Canada Launch follows announcement of commercial collaboration between Cogent International, a Vectura Fertin Pharma subsidiary, and Aurora to leverage Aurora's Canadian medical cannabis patient platform Collaboration will explore the potential to launch Vectura Fertin Pharma's future medical cannabis portfolio in Canada EDMONTON, AB, and STAMFORD, Conn. , Sept. 9, 2024 /PRNewswire/ - Aurora Cannabis Inc. ("Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canadian-based global medical cannabis company, and Vectura Fertin Pharma, Inc., an innovator in wellness and healthcare, are pleased to announce the launch of the newly developed Luo CBD lozenge.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
